NCT05926583View on ClinicalTrials.gov

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

PHASE3RecruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 12, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

November 12, 2030

Conditions
Retinitis Pigmentosa
Interventions
GENETIC

AAV5-hRKp.RPGR

AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.

GENETIC

AAV5-hRKp.RPGR

AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.

Trial Locations (1)

1528902

RECRUITING

National Hospital Organization Tokyo Medical Center, Meguro-ku

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT05926583 - A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa | Biotech Hunter | Biotech Hunter